An examination of these changes, along with an overview of the challenges and future prospects, reveals a promising evolution in combating this traditionally difficult-to-treat cancer.
After years of stagnation, the treatment landscape for small cell lung cancer (SCLC) has begun to shift positively. The FDA’s recent approvals of immune checkpoint inhibitors (ICIs) atezolizumab and durvalumab offer new hope and options for patients and oncologists alike.
- FDA approved atezolizumab (Tecentriq) and durvalumab (Imfinzi) in 2019 and 2020 for extensive-stage SCLC.
- These approvals are based on findings from the IMpower133 trial and CASPIAN study.
- ICIs have shown to improve overall survival and decrease the chance of recurrence.
- New treatments have been embraced for their competitive response rate, especially as maintenance drugs.
- Traditional treatment has been platinum-etoposide chemotherapy; prognosis historically poor.
- Other trials, such as the CASPIAN trial, are promising but not yet FDA-approved.
- Challenges include late-stage presentation, rapid disease progression, and short disease-free progression periods.
- A team approach, involving medical oncologists, thoracic surgeons, radiation oncologists, and pulmonologists, is emphasized.
- There’s a focus on early detection through low-dose CT scans for chronic smokers.
- The integration of immune checkpoint inhibitors into the treatment protocol, coupled with a comprehensive team approach, marks a hopeful shift in the management of SCLC. The focus on early detection and continued research may further revolutionize treatment in the coming years.
Pulmonology Latest Posts
- Radiologists Outperform AI in Identifying Lung Diseases on Chest X-rays
- Combo Vaccine for Influenza and COVID-19 Looks Promising in Early Study
- MKSAP Quiz: Evaluation for Pneumonia
- RSV Vaccines New Tool for Physicians
Did You Know?
The traditional 5-year survival rate for patients with extensive-stage small cell lung cancer is just 1% to 2%.